The new HbA1c test has a reportable range of 20 to 130 mmol/mol HbA1c. Credit: LumiraDx / PRNewswire.

LumiraDx has reported that its HbA1c test received CE mark for the screening and monitoring of people with diabetes in the point of care (POC) setting.

The rapid microfluidic immunofluorescence assay is used with the portable LumiraDx Platform and provides results in less than seven minutes from sample application.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Furthermore, the automated, quantitative fingerstick assay can aid in screening and detecting patients at risk of developing diabetes.

Adding HbA1c to the LumiraDx test menu also facilitates the merging of various instruments to a single POC Platform with a shared workflow. 

The new HbA1c test has a reportable range of 20 to 130 mmol/mol HbA1c. 

See Also:

According to data from an external, multisite clinical trial, the test was shown to attain a precision of ≤2.50% in capillary and venous whole blood as measured by mean paired replicate %CV. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company noted that the test is intended to meet the rising clinical demand for reliable HbA1c testing in the community healthcare setting.

The test will be offered on the same POC Platform as the company’s high sensitivity SARS-CoV-2 Antigen, Flu A/B, RSV, SARS-CoV-2 Antibody, SARS-CoV-2 Antigen Pool and SARS-CoV-2 Ag Ultra as well as INR, D-Dimer and CRP tests.

LumiraDx CEO Ron Zwanziger said: “With our growing test menu, the LumiraDx Platform is able to quickly and accurately support clinicians with a variety of diagnostic and treatment decisions at the point of care. 

“HbA1c is an important addition to our platform not only for our existing pharmacy and primary care customers but for new customers looking to consolidate their current testing needs into one centralised and streamlined, connected platform that delivers lab comparable performance.”

The latest development comes after the World Health Organization (WHO) granted Emergency Use Listing (EUL) for the company’s rapid antigen assay for Covid-19 detection.